Cardiac death risk in relation to the age at initiation or the progestin component of hormone therapies

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 7, 2016, Pages 2794-2801

  Savolainen Peltonen, Hanna ^a,b   Tuomikoski, Pauliina ^a   Korhonen, Pasi ^c   Hoti, Fabian ^c   Vattulainen, Pia ^c   Gissler, Mika ^d   Ylikorkala, Olavi ^a   Mikkola, Tomi S ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FOLKHÄLSAN RESEARCH CENTER   (Finland)

^c EPID Research Oy   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; TIBOLONE; CONJUGATED ESTROGEN;

ADULT; AGE; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY RISK; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; STANDARDIZED MORTALITY RATIO; ADVERSE EFFECTS; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; ESTROGEN THERAPY; MIDDLE AGED; MORTALITY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

AGE FACTORS; CASE-CONTROL STUDIES; CORONARY DISEASE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; PROGESTINS; RISK FACTORS; TIME FACTORS;

EID: 84978419045     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-4149     Document Type: Article

References (35)

1. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation: Commentary. Obstet Gynecol Surv. 2006;61: 392-394.
2. Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med. 2011;124:199-205.
3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary preventionofcoronary heart diseaseinpost-menopausal women. JAMA. 1998;280:605-613.
4. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. Aprospective, observational studyofpostmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
5. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascularfunction.Cardiovasc Res. 2002;53:605-619.
6. Hsia J, Langer RD, Manson JE, Kuller L, et al. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Arch Intern Med. 2006;166:357-365.
7. Kuhl H, Stevenson J. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits-an attempt to interpret the Women's Health Initiative results. Gynecol Endocrinol. 2006;22: 303-317.
8. Mirkin S, Amadio JM, Bernick BA, Pickar JH, Archer DF. 17ß-estradiol and natural progesterone for menopausal hormone ther-apy:REPLENISHphase3studydesignofacombinationcapsuleand evidence review. Maturitas. 2015;81:28-35.
9. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular eventsin recently postmeno-pausal women: randomised trial. BMJ (Online). 2012;345.
10. Smith NL, Blondon M, Wiggins KL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med. 2014;174:25-31.
11. Stanczyk FZ, Hapgood JP, Winer S, Mishell Jr. DR. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34:171-208.
12. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001;76:231-238.
13. Kwok S, Charlton-Menys V, Pemberton P, McElduff P, Durrington PN. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in post-menopausal women. Maturitas. 2006;53:439-446.
14. Schneider C, Jick SS, Meier CR. Risk of cardiovascular outcomes in users of estradioldydrogesterone or other HRT preparations. Climacteric. 2009;12:445-453.
15. Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based post-menopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause. 2015;22:976-983.
16. Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol. 2009;114:1197-1204.
17. Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1998.
18. Breslow NE, Day NE. Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Sci Publ no. 82. Lyon, France: International Agency for Research on Cancer; 1987.
19. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
20. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
21. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health. 2006;15:35-44.
22. Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women-A meta-analysis. J Gen Intern Med. 2006;21:363-366.
23. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477.
24. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol. 2009;170:12-23.
25. Pedersen NG, Pedersen SH, Dalsgaard T, Lund CO, Nilas L, Ottesen B. Progestins used in hormonal replacement therapy display different effects in coronary arteries from New Zealand white rabbits. Maturitas. 2004;49:304-314.
26. Cutini PH, Campelo AE, Massheimer VL. Differential regulation of endothelium behavior by progesterone and medroxyprogesterone acetate. J Endocrinol. 2014;220:179-193.
27. Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard Ø. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J. 2008;29:2660-2668.
28. Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, Grobbee DE. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J. 2006;27:746-755.
29. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. New Engl J Med. 2008;359:697-708.
30. Kenemans P, Bundred NJ, Foidart J, et al. Safety and efficacy of tibolone inbreast-cancer patients with vasomotor symptoms:adou-ble-blind, randomised, non-inferiority trial. Lancet Oncol. 2009; 10:135-146.
31. Rosano GMC, Vitale C, Fini M. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Ann N Y Acad Sci. 2006;1092:341-348.
32. Harman SM. Menopausal hormone treatment cardiovascular disease: another look at an unresolved conundrum. Fertil Steril. 2014; 101:887-897.
33. Shufelt CL, Merz CNB, Prentice RL, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative observational study. Menopause. 2014;21:260-266.
34. Topo P, Luoto R, Hemminki E, Uutela A. Declining socioeconomic differences in the use of menopausal and postmenopausal hormone therapy in Finland. Maturitas. 1999;32:141-145.
35. Lahti RA, Sarna S, Penttilä A. Exploitation of autopsy in determining natural cause of death: trends in Finland with special reference to the diagnostics of ischemic heart diseases and cerebrovascular diseases in middle-aged males, 1974-1993. Forensic Sci Int. 1998; 91:109-121.